Daily Sepsis Research Analysis
Analyzed 28 papers and selected 3 impactful papers.
Summary
Three studies advance sepsis science and practice: beta-blocker use in sepsis-induced myocardial injury was associated with lower mortality across two independent ICU databases; iatrogenic exposure to the plasticizer DEHP correlated with worse 28-day survival and implicated MAPK14-driven monocyte dysregulation; and baseline illness severity strongly modified the association between sepsis and survival in AKI, reversing from harm to benefit at highest severity.
Research Themes
- Targeted cardiovascular management in sepsis-induced myocardial injury
- Iatrogenic exposures in critical care and modifiable sepsis risk
- Heterogeneity and risk stratification in sepsis-associated AKI outcomes
Selected Articles
1. Association Between Beta-Blocker Use and Outcomes in Patients with Sepsis-Induced Myocardial Injury: An Analysis Based on MIMIC-IV and eICU Databases.
Across MIMIC-IV and eICU cohorts, ICU beta-blocker use in SIMI was associated with significantly lower in-hospital and long-term mortality after propensity score matching, with the largest benefit in the sickest patients. Findings were robust across multiple sensitivity analyses.
Impact: This large, two-database analysis identifies a potentially actionable therapy associated with survival benefits in a high-risk sepsis subgroup and motivates randomized testing.
Clinical Implications: Consider cautious, individualized beta-blockade for SIMI within hemodynamic limits, especially in severe cases, while awaiting randomized trials to define agents, timing, and dosing.
Key Findings
- After 1:1 propensity score matching, beta-blocker use was linked to lower in-hospital mortality in both MIMIC-IV (19.7% vs 29.9%; OR 0.75, 95% CI 0.60-0.94) and eICU (28.6% vs 35.1%; OR 0.70, 95% CI 0.56-0.88).
- Lower long-term mortality at 28 days, 90 days, and 1 year among beta-blocker users (all P<0.001).
- Greatest mortality reduction observed in severely ill patients (SOFA≥8), with ~55% relative reduction.
- Robustness supported by multiple sensitivity analyses (E-values 2.00–2.21) and consistent findings across databases.
Methodological Strengths
- Two independent, large ICU datasets (MIMIC-IV and eICU) with propensity score matching.
- Extensive sensitivity analyses and evaluation of short- and longer-term mortality.
Limitations
- Observational design with potential residual confounding and indication bias.
- Heterogeneity in beta-blocker type, dosing, and timing not fully standardized.
Future Directions: Prospective randomized trials of targeted beta-blockade in SIMI to define optimal agent, dose, timing, and patient selection, including hemodynamic safety profiles.
BACKGROUND: Sepsis-induced myocardial injury (SIMI) is a severe complication with high mortality. Beta-blocker therapy in SIMI remains controversial, lacking large-sample evidence. OBJECTIVE: To evaluate beta-blocker impact on mortality in SIMI patients using MIMIC-IV and eICU databases. METHODS: A retrospective cohort study based on MIMIC-IV (2008-2022) and eICU (2014-2015) databases included adult SIMI patients meeting Sepsis-3.0 criteria with elevated cardiac troponin. The primary exposure was beta-blocker use during ICU stay, and the primary outcome was in-hospital all-cause mortality. 1:1 propensity score matching was used to balance baseline characteristics, with multiple sensitivity analyses to verify result robustness. RESULTS: MIMIC-IV included 2,368 SIMI patients (1,338 using beta-blockers); eICU included 3,805 patients (1,030 using beta-blockers). After propensity score matching (MIMIC-IV: 837/group; eICU: 902/group), beta-blocker use was associated with a significant reduction in in-hospital mortality (MIMIC-IV: 19.7% vs 29.9%, OR=0.75, 95%CI: 0.60-0.94; eICU: 28.6% vs 35.1%, OR=0.70, 95%CI: 0.56-0.88). Long-term mortality was lower by 39% (28-day), 33% (90-day), and 27% (1-year) (all P<0.001). Multiple sensitivity analyses confirmed robustness (E-value: 2.00-2.21). Severely ill patients (SOFA≥8) had the greatest mortality reduction associated with beta-blocker use (55%). Prolonged hospital stay was consistent with a survival benefit rather than adverse effects. CONCLUSIONS: Beta-blocker use is associated with reduced mortality and better long-term survival in SIMI patients, requiring prospective validation.
2. Iatrogenic plasticizer Di(2-ethylhexyl) phthalate (DEHP) exposure increases Sepsis mortality risk: Machine learning implicates monocyte-driven immune dysregulation.
Prospective biomonitoring linked higher ICU DEHP exposure to worse 28-day survival in sepsis. Multi-omic integration and Mendelian randomization converged on MAPK14 as a key mediator, positioning DEHP as a modifiable iatrogenic risk and supporting evaluation of DEHP-free devices.
Impact: Identifies an actionable environmental exposure in critical care and triangulates mechanism using machine learning, docking, and genetic causal inference.
Clinical Implications: Hospitals should evaluate DEHP-free alternatives for high-leach devices and consider monitoring high-risk patients’ exposure while awaiting interventional evidence.
Key Findings
- Sepsis patients had significantly higher urinary DEHP metabolites than controls (p<0.001).
- High DEHP exposure (≥341.58 μg/g creatinine) independently associated with lower 28-day survival (35% vs 55%; HR 1.92, 95% CI 1.01-3.65).
- Integration of 7 sepsis transcriptomic datasets with DEHP targets identified 46 overlapping genes; ML prioritized 7 core genes with MAPK14 dominant by SHAP.
- Molecular docking supported high-affinity binding; Mendelian randomization linked higher genetically predicted MAPK14 expression to increased sepsis susceptibility (OR 1.18, p=0.045).
Methodological Strengths
- Prospective exposure assessment with LC-MS/MS and inclusion of a control group.
- Triangulation with machine learning, molecular docking, and Mendelian randomization.
Limitations
- Moderate sample size and likely single-center design limit generalizability.
- Observational exposure-outcome association; potential residual confounding and exposure misclassification; MR assumptions apply.
Future Directions: Cluster or stepped-wedge trials replacing high-leach devices with DEHP-free alternatives to test outcome effects; mechanistic validation of MAPK14-mediated monocyte dysfunction in vivo.
Sepsis poses a significant global health burden, and ICU patients are disproportionately exposed to di(2-ethylhexyl) phthalate (DEHP), an immunotoxic plasticizer that leaches from PVC medical devices; however, whether this exposure causally influences sepsis outcomes remains unclear. To investigate this relationship, we conducted a prospective cohort study comparing 90 ICU sepsis patients with 50 controls, quantifying urinary DEHP metabolites using LC-MS/MS. Sepsis patients demonstrated significantly elevated DEHP metabolite levels (p < 0.001), and high exposure (≥341.58 μg/g creatinine) was independently associated with reduced 28-day survival (35% vs 55%, p = 0.04; HR = 1.92, 95%CI:1.01-3.65). To identify the molecular mechanisms underlying this association, we integrated seven sepsis transcriptomic datasets with predicted DEHP targets, revealing 46 overlapping genes. Subsequently, machine learning algorithms (LASSO, SVM-RFE, and Random Forest) prioritized seven core genes, with SHAP analysis identifying MAPK14 as the predominant contributor. Molecular docking further confirmed high-affinity binding between DEHP and these target proteins. To establish causality, Mendelian randomization analysis using cis-eQTLs and FinnGen GWAS data demonstrated that genetically predicted higher MAPK14 expression increases sepsis susceptibility (OR = 1.18, p = 0.045). In conclusion, these findings provide converging evidence that high iatrogenic DEHP exposure is associated with increased sepsis mortality, potentially through MAPK14-mediated pathways, suggesting that DEHP exposure represents a modifiable risk factor in critical care settings and supporting the evaluation of DEHP-free alternatives for high-leach medical devices.
3. Illness severity modifies the association between sepsis and survival in critically ill patients with acute kidney injury.
In 35,926 ICU patients with AKI, baseline illness severity markedly modified the sepsis–survival association: harm at low severity but improved survival at highest severity, with a 27.9-point reversal. Findings challenge uniform risk assumptions and refine prognostication.
Impact: Large-scale evidence reveals effect modification that may reframe prognostic models and clinical triage in septic AKI.
Clinical Implications: Integrate illness severity when prognosticating septic AKI and avoid therapeutic nihilism in the sickest; design trials that stratify by baseline severity.
Key Findings
- Significant interaction between sepsis and SAPS II on 30-day survival (p<0.001).
- At SAPS II=20, sepsis reduced 30-day survival by 4.3 percentage points; at SAPS II=90, it increased survival by 23.6 points (27.9-point reversal).
- Results were robust across sensitivity analyses and multivariable adjustments.
Methodological Strengths
- Very large cohort with standardized Sepsis-3 definition and multivariable modeling.
- Explicit interaction testing with sensitivity analyses.
Limitations
- Retrospective design with potential misclassification and residual confounding.
- Generalizability may be limited by setting and data sources.
Future Directions: Prospective validation and mechanistic studies to explain the paradox; incorporate severity-stratified approaches into AKI prognostic tools and interventional trials.
BACKGROUND: Sepsis and acute kidney injury (AKI) are common, often co-occurring ICU syndromes with high mortality. Although illness severity scores such as the Simplified Acute Physiology Score II (SAPS II) are powerful prognostic tools, it is unclear whether baseline illness severity modifies the relationship between sepsis and mortality in AKI. We hypothesized that this association varies across the severity spectrum. METHODS: In a retrospective cohort of 35,926 adults with AKI, we examined the interaction between sepsis (Sepsis-3 criteria) and baseline illness severity (SAPS II) in relation to 30-day survival. We used multivariable logistic regression adjusted for demographics, comorbidities, and organ dysfunction. RESULTS: A significant interaction between sepsis and illness severity was observed (p < 0.001). At low severity (SAPS II = 20), sepsis was associated with a 4.3 percentage point reduction in 30-day survival, whereas at high severity (SAPS II = 90), it was associated with a 23.6 percentage point increase in survival, representing a net reversal of 27.9 percentage points. This pattern was robust in sensitivity analyses. CONCLUSIONS: In critically ill patients with AKI, the impact of sepsis on survival is strongly modified by baseline illness severity, reversing from harm at low severity to improved survival at high severity. This paradox challenges the assumption of uniform sepsis risk and suggests that, in the sickest patients, sepsis may indicate a state of potentially reversible organ dysfunction. Incorporating illness severity into AKI prognostication may better capture recovery potential, as severity scores alone may underestimate the likelihood of recovery in severe septic AKI.